Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting
- PMID: 2407166
- DOI: 10.7326/0003-4819-112-5-328
Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting
Abstract
Study objective: To determine the sensitivity, specificity, and predictive value of Hemoccult II tests for detecting colorectal neoplasm (colorectal carcinoma or polyp or both).
Study design: Prospective analyses of asymptomatic patients (greater than or equal to 45 years) followed for 4 years after screening with Hemoccult II testing and retrospective analyses of patients, with known colorectal carcinoma or polyps or both who had Hemoccult II testing within 2 years of diagnosis.
Setting: A large, health maintenance organization practice.
Measurements and main results: In the prospective analysis, the sensitivity of Hemoccult II was 50% for colorectal carcinoma diagnosed within 1 year of testing, 43% within 2 years, and 25% within 4 years. For polyps, sensitivity was 36% at 1 year, 28% at 2 years, and 17% at 4 years. Specificity was 99%. The predictive value of a positive test for colorectal carcinoma was 8% at 1 year, 10% at 2 years, and 11% at 4 years. On the basis of the retrospective analyses, the sensitivity of Hemoccult II for colorectal carcinoma diagnosed within 1 year of testing was 66% and was 61% within 2 years. Many of these patients had symptoms when tested.
Conclusions: An asymptomatic patient age 45 or older with a positive Hemoccult II test has about a chance of 1 in 10 for having colorectal carcinoma and a 1-in-3 chance of having either a colorectal carcinoma or polyp: The same patient with a negative Hemoccult test has a 0.2% chance of having a colorectal carcinoma diagnosed within 2 years of testing and a 0.7% chance of having a polyp. Within 4 years of testing the chance increases to 0.5% for colorectal carcinoma and 1.5% for polyps. If Hemoccult II slides are the only screening method used for detecting asymptomatic colorectal neoplasms, 50% to 60% of lesions will remain undetected. Clinical interpretation of Hemoccult screening requires appreciation of its limits as well as its benefits.
Comment in
-
Screening for colorectal cancer.Ann Intern Med. 1990 Aug 15;113(4):333-4. doi: 10.7326/0003-4819-113-4-333_1. Ann Intern Med. 1990. PMID: 2242156 No abstract available.
-
Hemoccult screening and colorectal neoplasms.Ann Intern Med. 1990 Jun 1;112(11):880-1. doi: 10.7326/0003-4819-112-11-880. Ann Intern Med. 1990. PMID: 2344114 No abstract available.
Similar articles
-
A comparison of fecal occult-blood tests for colorectal-cancer screening.N Engl J Med. 1996 Jan 18;334(3):155-9. doi: 10.1056/NEJM199601183340304. N Engl J Med. 1996. PMID: 8531970
-
Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy.Am J Gastroenterol. 1995 Nov;90(11):1974-7. Am J Gastroenterol. 1995. PMID: 7485003
-
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.JAMA. 1993 Mar 10;269(10):1262-7. JAMA. 1993. PMID: 8437303 Clinical Trial.
-
Fecal occult blood testing: clinical value and limitations.Gastroenterologist. 1998 Mar;6(1):66-78. Gastroenterologist. 1998. PMID: 9531118 Review.
-
Screening for colorectal cancer by immunochemical fecal occult blood testing.Jpn J Cancer Res. 1996 Oct;87(10):1011-24. doi: 10.1111/j.1349-7006.1996.tb03103.x. Jpn J Cancer Res. 1996. PMID: 8957057 Free PMC article. Review.
Cited by
-
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.BMC Health Serv Res. 2013 Mar 19;13:105. doi: 10.1186/1472-6963-13-105. BMC Health Serv Res. 2013. PMID: 23510135 Free PMC article.
-
Colorectal cancer after a negative Haemoccult II test and programme sensitivity after a first round of screening: the experience of the Department of Calvados (France).Br J Cancer. 1999 Sep;81(2):305-9. doi: 10.1038/sj.bjc.6990692. Br J Cancer. 1999. PMID: 10496357 Free PMC article.
-
Detection of colorectal cancer in symptomatic outpatients without visible rectal bleeding: Validity of the fecal occult blood test.Clin Epidemiol. 2009 Aug 9;1:119-24. doi: 10.2147/clep.s7097. Clin Epidemiol. 2009. PMID: 20865093 Free PMC article.
-
Colorectal cancer screening: you can't be positive about a negative result.CMAJ. 2001 Oct 30;165(9):1248. CMAJ. 2001. PMID: 11706920 Free PMC article. No abstract available.
-
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval.Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1517-1520. doi: 10.1158/1055-9965.EPI-22-0232. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35916602 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical